Drug Database
MO

mometasone furoate (Monovo / H527722 / Mundoson)

✓ Approved

Almirall, S.A · NR3C1 · Small Molecule

What is mometasone furoate?

mometasone furoate is a small molecule developed by Almirall, S.A. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesMonovo, H527722, Mundoson
CompanyAlmirall, S.A
Drug ClassSmall Molecule
Molecular TargetNR3C1, NR3C2
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Almirall, S.A

Mechanism of Action

Molecular Targets

mometasone furoate acts on 2 molecular targets:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
NR3C2nuclear receptor subfamily 3 group C member 2 (NR3C2VIT, MR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

mometasone furoate is developed for 3 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersDermatitis allergic✓ Approved
Skin and subcutaneous tissue disordersDermatitis atopic✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

Related Research Articles

PubMedReports (MDPI)2026-07-24

Transnasal Endoscopic Repair of Unilateral Choanal Atresia in a Young Adult Using a Cross-Over Nasoseptal Flap Technique and a Bioabsorbable Mometasone-Furoate-Eluting Stent: A Case Report.

Vlachodimitropoulos Athanasios A, Mastronikolis Nicholas S NS, Danielides Gerasimos G, Tsapardoni Foteini F et al.

Background and Clinical Significance: Choanal atresia is a rare congenital obstruction of the posterior nasal aperture, with an estimated incidence of one in 5000 to one in 8000 live births. Bilateral disease typically presents as a neonatal emergency, whereas unilateral disease is more frequent and may remain undiagnosed for years or decades, presenting in adolescence or adulthood with chronic unilateral nasal obstruction and ipsilateral mucopurulent rhinorrhoea. Optimal surgical management remains debated, particularly with regard to mucosal-flap reconstruction and the choice of postoperative stent. Case Presentation: A 22-year-old male was referred for chronic left-sided nasal obstruction, persistent ipsilateral mucopurulent rhinorrhoea and reduced ipsilateral olfaction. Nasal endoscopy and high-resolution computed tomography demonstrated an isolated, non-syndromic, mixed bony-membranous left choanal atresia. The patient underwent transnasal endoscopic choanoplasty with posterior septectomy and removal of the atretic plate and posterior vomer. An ipsilateral superiorly based septal mucoperichondrial flap was raised first and later transposed over the sphenoid rostrum; following drilling, the contralateral septal mucosa was approached and incised horizontally to generate a superior and an inferior leaflet, which were rotated to cover the corresponding portions of the residual posterior septal ridge. A bioabsorbable mometasone-furoate-eluting sinus implant (PROPEL®, Medtronic) was deployed across the neo-choana. The follow-up endoscopy at two months demonstrated a widely patent, well-mucosalized neo-choana with complete resolution of symptoms. Conclusions: Transnasal endoscopic posterior septectomy combined with mucosal-flap reconstruction and a bioabsorbable steroid-eluting stent is a technically feasible and biologically rational approach to adult unilateral CA. To our knowledge, this is among the first reports describing the off-label intraoperative use of a PROPEL® stent in a young adult with isolated unilateral choanal atresia.

PMID 42496497
Read full article →
PubMedCureus2026-07-23

Extensive Pustular Tinea Incognita During Late Pregnancy: A Case Report.

Vilela Beatriz F BF, Fialho M C MC, Neves José M JM

Tinea incognita is an atypical presentation of dermatophytosis, usually modified by prior corticosteroid exposure, which may obscure the clinical diagnosis and mimic inflammatory dermatoses. We report the case of a 27-year-old woman at 35 weeks of gestation who presented with a three-week history of painful inflammatory lesions involving the gluteal region and posterior thighs. The eruption initially presented as bilateral erythema of the inguinal folds and gluteal area and worsened rapidly after topical mometasone treatment. Physical examination revealed extensive, symmetrical, well-demarcated erythematous plaques with fine scaling and numerous peripheral pustules. Given the pustular morphology and pregnancy context, pustular psoriasis was initially considered. However, direct mycological examination was positive, and fungal culture subsequently identified Trichophyton rubrum, confirming the diagnosis of pustular tinea incognita. Treatment with oral itraconazole led to marked clinical improvement. This case highlights the importance of considering dermatophytosis in the differential diagnosis of pustular eruptions during pregnancy, particularly when lesions worsen after topical corticosteroid use. Early mycological testing can prevent diagnostic delay and inappropriate escalation of anti-inflammatory or immunosuppressive therapy.

PMID 42488289
Read full article →
PubMedAdvances in therapy2026-07-20

Clinical Remission with FF/UMEC/VI Versus ICS/LABA in Uncontrolled Asthma: The PERFORM Pragmatic Randomized Controlled Trial.

Noorduyn Stephen G SG, Oppenheimer John J JJ, Moore Alison C AC, Nagase Hiroyuki H et al.

Prospective, randomized evidence for clinical remission, an ambitious treatment goal relevant for all patients with asthma, with single-inhaler triple therapy (SITT) in routine care is lacking. Significant improvement in lung function and asthma control with SITT versus inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) was demonstrated in PERFORM at week 24. PERFORM (GSK 219912/NCT06372496), a randomized, open-label, active-controlled, global pragmatic trial, evaluated the effectiveness and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus usual care ICS/LABA in adults (18-75 years) with uncontrolled, infrequently exacerbating asthma. Secondary outcomes related to clinical remission (no oral corticosteroid use, no severe exacerbations, optimized lung function [change from baseline (CFB) in forced expiratory volume in 1 second (FEV1) ≥ 100 mL], asthma control [Asthma Control Questionnaire total score < 1.50]) were assessed at week 52, following prespecified analysis plans. Alternative clinical remission definitions using stabilized lung function (CFB FEV1 ≥ 0 mL) and those within Japanese guidelines were also assessed. Clinical remission responder analyses are presented as multiplicity-adjusted odds ratios. Safety was assessed throughout. Overall, 1236 participants (mean age 48.9 years; 68.6% [n = 848/1236] female) were included (FF/UMEC/VI: N = 619/1236; ICS/LABA: N = 617/1236). Participants receiving FF/UMEC/VI had statistically significantly greater odds of achieving clinical remission (including optimized lung function) at week 52 versus usual care ICS/LABA (adjusted odds ratio [95% confidence interval] 2.13 [1.54, 2.94], P < 0.0001). Similar results were observed for alternative definitions. Week 52 safety profile aligned with previous studies. In a broad patient population with uncontrolled asthma, treatment with FF/UMEC/VI resulted in statistically significantly greater odds of achieving clinical remission versus usual care ICS/LABA in a setting reflecting routine practice, a secondary outcome of PERFORM. These findings were consistent irrespective of clinical remission definitions and provide evidence informing the use of FF/UMEC/VI in an underserved group of symptomatic patients with infrequent exacerbations and minimal lung function impairment. GSK 219912/NCT06372496.

PMID 42474701
Read full article →
PubMedJournal of clinical medicine2026-07-15

Correction: Akiyama et al. Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan. J. Clin. Med. 2025, 14, 4697.

Akiyama Shoko S, Oda Kenji K, Mizohata Hiroko H, Sasakura Natsuki N et al.

There was an error in the original publication [...].

PMID 42452781
Read full article →
PubMedJournal of family medicine and primary care2026-07-15

Awareness, knowledge, attitude, and behaviors related to topical corticosteroid use among population in Hail, Saudi Arabia: A cross-sectional study.

Aljaloud Luluh Zamil LZ, Altamimi Naif N, Alharthi Reem Marzouq S RMS, Alghamdi Mohammed Saeed Mohammed MSM et al.

Corticosteroids are widely used for inflammatory conditions, yet misuse and limited public awareness can cause preventable harm. In Hail, Saudi Arabia, community knowledge appears limited, warranting targeted assessment. To assess knowledge, awareness, attitudes, and use patterns of topical corticosteroids (TCSs) among adults in Hail, Saudi Arabia. We conducted a cross-sectional online survey (October 2024-March 2025) among adults aged ≥18 years. Of 535 respondents, 419 (78.0%) reported prior TCS use and were included in behavioral analyses, while 116 (21.0%) were non-users. Descriptive statistics summarized patterns, and bivariate analyses examined associations between awareness and behaviors. Prescription use was more common than self-medication (58.9% vs 41.1%), and most users applied corticosteroids once daily (60.6%). Mometasone was the most frequently reported agent (33.9%), although 36.8% could not name the product; acne, melasma, and tinea were common indications. Awareness was moderate: 62.8% recognized potency categories, and 55.4% were aware of adverse effects. Overall, 45.0% reported ≥1 adverse effect, most often mood changes, pruritus, increased thirst/urination, or skin thinning. Most had discontinued at least once (79.5%); tapering was more frequent than abrupt cessation (58.9% vs 41.1%), and relapse occurred in 23.7%, often within a week. Awareness aligned with safer practice: aware users were more likely to have a prescription (65.0% vs 48.7%) and to recognize adverse effects (73.8% vs 24.4%); prescribed users also tapered more often than they stopped abruptly (67.6% vs 43.9%). TCS use is prevalent in Hail and is accompanied by self-medication and important knowledge deficits. Strengthening pharmacist counseling, improving labeling, regulating access to higher-potency agents, and implementing community education initiatives may enhance safety and reduce avoidable adverse outcomes.

PMID 42453254
Read full article →
PubMedImmunity, inflammation and disease2026-07-14

Mometasone Furoate Alleviates PM2.5-Induced Pyroptosis of Nasal Mucosa Cells via Blocking JAK2/STAT3/AIM2 Inflammasome.

Shi Bin B, Liu Zhiqi Z, Le Ge G

Mometasone furoate (MF) is a widely used intranasal corticosteroid for the management of allergic and non-allergic rhinitis. Recent evidence suggests that its therapeutic efficacy may involve mechanisms beyond traditional anti-inflammatory actions, including modulation of death in nasal mucosa cells. This study aimed to investigate the therapeutic effects of MF on chronic rhinitis, elucidates the underlying molecular mechanisms, and explores its clinical implications in rhinitis management. Enzyme-linked immunosorbent assay was used to detect cytokine release. Reverse transcription quantitative PCR was applied for detecting mRNA expression. Immunofluorescence was used detect LC3 expression. Protein express was detected using Western blot. Lactate dehydrogenase leakage assay was used to detect cytotoxicity. Terminal deoxynucleotidyl transferase dUTP nick-end labeling assay was used to detect death of nasal mucosa cells (NMCs). Luciferase and chromatin immunoprecipitation assays were used to verify the interaction between signal transducer and activator of transcription 3 (STAT3) and absent in melanoma 2 (AIM2). MF significantly suppressed inflammatory response induced by PM2.5. MF suppressed PM2.5-induced cytotoxicity and pyroptosis of NMCs. Moreover, MF promotes the activation of autophagy. Mechanically, MF inhibited PM2.5-induced activation of Janus kinase 2/STAT3 signaling. STAT3 transcriptionally upregulated AIM2. The activation of AIM2 inflammasome attenuated the effects of MF and promoted the inflammation and pyroptosis of NMCs as well as suppressed the activation of autophagy. In summary, MF protects against chronic rhinitis via suppressing AIM2-dependent pyroptosis of NMCs. Therefore, MF can be a therapeutic strategy for chronic rhinitis.

PMID 42444306
Read full article →

+2108 more articles available with a free account

Sign up free to view all articles →

Ask about mometasone furoate